Biogen Net Worth
Biogen Net Worth Breakdown | BIIB |
Biogen Net Worth Analysis
Biogen's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Biogen's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Biogen's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Biogen's net worth analysis. One common approach is to calculate Biogen's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Biogen's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Biogen's net worth. This approach calculates the present value of Biogen's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Biogen's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Biogen's net worth. This involves comparing Biogen's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Biogen's net worth relative to its peers.
Enterprise Value |
|
To determine if Biogen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biogen's net worth research are outlined below:
| Biogen Inc generated a negative expected return over the last 90 days | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Biogen Appoints Sean Godbout as Vice President and Chief Accounting Officer |
Biogen Quarterly Good Will |
|
Biogen uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biogen Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biogen's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 23rd of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Biogen Target Price Consensus
Biogen target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Biogen's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 34 | Buy |
Most Biogen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Biogen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Biogen Inc, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBiogen Target Price Projection
Biogen's current and average target prices are 146.23 and 231.77, respectively. The current price of Biogen is the price at which Biogen Inc is currently trading. On the other hand, Biogen's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Biogen Market Quote on 30th of January 2025
Target Price
Analyst Consensus On Biogen Target Price
Know Biogen's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biogen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biogen Inc backward and forwards among themselves. Biogen's institutional investor refers to the entity that pools money to purchase Biogen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Beutel, Goodman & Company Ltd. | 2024-09-30 | 1.7 M | Amvescap Plc. | 2024-09-30 | 1.6 M | Legal & General Group Plc | 2024-09-30 | 1.5 M | Northern Trust Corp | 2024-09-30 | 1.4 M | Ra Capital Management, Llc | 2024-09-30 | 1.2 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 1.2 M | Ameriprise Financial Inc | 2024-09-30 | 1.2 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.1 M | Bank Of New York Mellon Corp | 2024-09-30 | 1 M | Vanguard Group Inc | 2024-09-30 | 16.7 M | Primecap Management Company | 2024-09-30 | 16.3 M |
Follow Biogen's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 21.04 B.Market Cap |
|
Project Biogen's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.09 | 0.08 | |
| Return On Capital Employed | 0.08 | 0.08 | |
| Return On Assets | 0.04 | 0.06 | |
| Return On Equity | 0.07 | 0.10 |
When accessing Biogen's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Biogen's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biogen's profitability and make more informed investment decisions.
Please note, the presentation of Biogen's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biogen's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biogen's management manipulating its earnings.
Evaluate Biogen's management efficiency
Biogen Inc has return on total asset (ROA) of 0.0499 % which means that it generated a profit of $0.0499 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1047 %, meaning that it created $0.1047 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biogen's Return On Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.1, whereas Return On Tangible Assets are forecasted to decline to 0.08. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 24.1 B, whereas Non Currrent Assets Other are forecasted to decline to about 310.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 92.05 | 96.65 | |
| Tangible Book Value Per Share | 1.35 | 1.28 | |
| Enterprise Value Over EBITDA | 16.56 | 17.39 | |
| Price Book Value Ratio | 2.91 | 2.76 | |
| Enterprise Value Multiple | 16.56 | 17.39 | |
| Price Fair Value | 2.91 | 2.76 | |
| Enterprise Value | 6.4 B | 4.2 B |
The operational strategies employed by Biogen management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 2.7221 | Revenue | Quarterly Revenue Growth (0.03) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biogen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biogen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biogen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mantas Jesus B over a month ago Acquisition by Mantas Jesus B of 1340 shares of Biogen subject to Rule 16b-3 | ||
Singhal Priya over three months ago Disposition of 1668 shares by Singhal Priya of Biogen subject to Rule 16b-3 | ||
Singhal Priya over six months ago Disposition of tradable shares by Singhal Priya of Biogen at 213.09 subject to Rule 16b-3 | ||
Ginger Gregory over six months ago Disposition of 634 shares by Ginger Gregory of Biogen at 240.98 subject to Rule 16b-3 | ||
Douglas Williams over a year ago Sale by Douglas Williams of 916 shares of Biogen |
Biogen Corporate Filings
8K | 15th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 10th of January 2025 Other Reports | ViewVerify | |
F3 | 7th of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
F4 | 9th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Biogen Earnings Estimation Breakdown
The calculation of Biogen's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Biogen is estimated to be 4.104175 with the future projection ranging from a low of 4.035 to a high of 4.299925. Please be aware that this consensus of annual earnings estimates for Biogen Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
4.04 Lowest | Expected EPS | 4.30 Highest |
Biogen Earnings Projection Consensus
Suppose the current estimates of Biogen's value are higher than the current market price of the Biogen stock. In this case, investors may conclude that Biogen is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Biogen's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 35 | 89.09% | 4.08 | 4.104175 | 11.06 |
Biogen Earnings per Share Projection vs Actual
Actual Earning per Share of Biogen refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Biogen Inc predict the company's earnings will be in the future. The higher the earnings per share of Biogen, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Biogen Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Biogen, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Biogen should always be considered in relation to other companies to make a more educated investment decision.Biogen Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Biogen's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-10-30 | 2024-09-30 | 3.79 | 4.08 | 0.29 | 7 | ||
2024-08-01 | 2024-06-30 | 4.03 | 5.28 | 1.25 | 31 | ||
2024-04-24 | 2024-03-31 | 3.45 | 3.67 | 0.22 | 6 | ||
2024-02-13 | 2023-12-31 | 3.18 | 3.3 | 0.12 | 3 | ||
2023-11-08 | 2023-09-30 | 3.97 | 4.36 | 0.39 | 9 | ||
2023-07-25 | 2023-06-30 | 3.77 | 4.02 | 0.25 | 6 | ||
2023-04-25 | 2023-03-31 | 3.28 | 3.4 | 0.12 | 3 | ||
2023-02-15 | 2022-12-31 | 3.48 | 4.05 | 0.57 | 16 | ||
2022-10-25 | 2022-09-30 | 4.14 | 4.77 | 0.63 | 15 | ||
2022-07-20 | 2022-06-30 | 4.06 | 5.25 | 1.19 | 29 | ||
2022-05-03 | 2022-03-31 | 4.38 | 4.38 | 0.0 | 0 | ||
2022-02-03 | 2021-12-31 | 3.38 | 3.39 | 0.01 | 0 | ||
2021-10-20 | 2021-09-30 | 4.09 | 4.77 | 0.68 | 16 | ||
2021-07-22 | 2021-06-30 | 4.54 | 5.68 | 1.14 | 25 | ||
2021-04-22 | 2021-03-31 | 5.04 | 5.34 | 0.3 | 5 | ||
2021-02-03 | 2020-12-31 | 4.87 | 4.58 | -0.29 | 5 | ||
2020-10-21 | 2020-09-30 | 8.04 | 8.84 | 0.8 | 9 | ||
2020-07-22 | 2020-06-30 | 8.03 | 10.26 | 2.23 | 27 | ||
2020-04-22 | 2020-03-31 | 7.73 | 9.14 | 1.41 | 18 | ||
2020-01-30 | 2019-12-31 | 8.02 | 8.34 | 0.32 | 3 | ||
2019-10-22 | 2019-09-30 | 8.27 | 9.17 | 0.9 | 10 | ||
2019-07-23 | 2019-06-30 | 7.53 | 9.15 | 1.62 | 21 | ||
2019-04-24 | 2019-03-31 | 6.87 | 6.98 | 0.11 | 1 | ||
2019-01-29 | 2018-12-31 | 6.73 | 6.99 | 0.26 | 3 | ||
2018-10-23 | 2018-09-30 | 6.78 | 7.4 | 0.62 | 9 | ||
2018-07-24 | 2018-06-30 | 5.21 | 5.8 | 0.59 | 11 | ||
2018-04-24 | 2018-03-31 | 5.94 | 6.05 | 0.11 | 1 | ||
2018-01-25 | 2017-12-31 | 5.45 | 5.26 | -0.19 | 3 | ||
2017-10-24 | 2017-09-30 | 5.73 | 6.31 | 0.58 | 10 | ||
2017-07-25 | 2017-06-30 | 4.41 | 5.04 | 0.63 | 14 | ||
2017-04-25 | 2017-03-31 | 4.97 | 5.2 | 0.23 | 4 | ||
2017-01-26 | 2016-12-31 | 4.96 | 5.04 | 0.08 | 1 | ||
2016-10-26 | 2016-09-30 | 4.97 | 5.19 | 0.22 | 4 | ||
2016-07-21 | 2016-06-30 | 4.67 | 5.21 | 0.54 | 11 | ||
2016-04-21 | 2016-03-31 | 4.47 | 4.79 | 0.32 | 7 | ||
2016-01-27 | 2015-12-31 | 4.08 | 4.5 | 0.42 | 10 | ||
2015-10-21 | 2015-09-30 | 3.8 | 4.48 | 0.68 | 17 | ||
2015-07-24 | 2015-06-30 | 4.1 | 4.22 | 0.12 | 2 | ||
2015-04-24 | 2015-03-31 | 3.91 | 3.82 | -0.09 | 2 | ||
2015-01-29 | 2014-12-31 | 3.78 | 4.09 | 0.31 | 8 | ||
2014-10-22 | 2014-09-30 | 3.46 | 3.8 | 0.34 | 9 | ||
2014-07-23 | 2014-06-30 | 2.83 | 3.34 | 0.51 | 18 | ||
2014-04-23 | 2014-03-31 | 2.55 | 2.47 | -0.08 | 3 | ||
2014-01-29 | 2013-12-31 | 2.28 | 2.34 | 0.06 | 2 | ||
2013-10-28 | 2013-09-30 | 2.1 | 2.35 | 0.25 | 11 | ||
2013-07-25 | 2013-06-30 | 1.93 | 2.3 | 0.37 | 19 | ||
2013-04-25 | 2013-03-31 | 1.61 | 1.97 | 0.36 | 22 | ||
2013-01-28 | 2012-12-31 | 1.46 | 1.4 | -0.06 | 4 | ||
2012-10-25 | 2012-09-30 | 1.6 | 1.91 | 0.31 | 19 | ||
2012-07-24 | 2012-06-30 | 1.56 | 1.82 | 0.26 | 16 | ||
2012-05-01 | 2012-03-31 | 1.48 | 1.4 | -0.08 | 5 | ||
2012-01-31 | 2011-12-31 | 1.49 | 1.51 | 0.02 | 1 | ||
2011-10-28 | 2011-09-30 | 1.53 | 1.61 | 0.08 | 5 | ||
2011-07-26 | 2011-06-30 | 1.37 | 1.36 | -0.01 | 0 | ||
2011-04-21 | 2011-03-31 | 1.41 | 1.43 | 0.02 | 1 | ||
2011-02-01 | 2010-12-31 | 1.23 | 1.42 | 0.19 | 15 | ||
2010-10-26 | 2010-09-30 | 1.22 | 1.35 | 0.13 | 10 | ||
2010-07-20 | 2010-06-30 | 1.12 | 1.31 | 0.19 | 16 | ||
2010-04-20 | 2010-03-31 | 1.13 | 1.08 | -0.05 | 4 | ||
2010-02-09 | 2009-12-31 | 1.05 | 1.2 | 0.15 | 14 | ||
2009-10-20 | 2009-09-30 | 1.04 | 1.12 | 0.08 | 7 | ||
2009-07-16 | 2009-06-30 | 0.68 | 0.75 | 0.07 | 10 | ||
2009-04-16 | 2009-03-31 | 1 | 1.05 | 0.05 | 5 | ||
2009-02-06 | 2008-12-31 | 0.93 | 0.93 | 0.0 | 0 | ||
2008-10-21 | 2008-09-30 | 0.9 | 0.98 | 0.08 | 8 | ||
2008-07-22 | 2008-06-30 | 0.85 | 0.91 | 0.06 | 7 | ||
2008-04-23 | 2008-03-31 | 0.79 | 0.83 | 0.04 | 5 | ||
2008-02-06 | 2007-12-31 | 0.8 | 0.89 | 0.09 | 11 | ||
2007-10-23 | 2007-09-30 | 0.65 | 0.58 | -0.07 | 10 | ||
2007-07-24 | 2007-06-30 | 0.63 | 0.7 | 0.07 | 11 | ||
2007-05-02 | 2007-03-31 | 0.61 | 0.59 | -0.02 | 3 | ||
2007-02-15 | 2006-12-31 | 0.55 | 0.53 | -0.02 | 3 | ||
2006-10-31 | 2006-09-30 | 0.49 | 0.6 | 0.11 | 22 | ||
2006-07-26 | 2006-06-30 | 0.49 | 0.57 | 0.08 | 16 | ||
2006-04-26 | 2006-03-31 | 0.48 | 0.55 | 0.07 | 14 | ||
2006-02-15 | 2005-12-31 | 0.47 | 0.48 | 0.01 | 2 | ||
2005-10-26 | 2005-09-30 | 0.42 | 0.36 | -0.06 | 14 | ||
2005-07-26 | 2005-06-30 | 0.36 | 0.43 | 0.07 | 19 | ||
2005-04-27 | 2005-03-31 | 0.36 | 0.3 | -0.06 | 16 | ||
2005-02-07 | 2004-12-31 | 0.36 | 0.29 | -0.07 | 19 | ||
2004-10-27 | 2004-09-30 | 0.35 | 0.37 | 0.02 | 5 | ||
2004-07-28 | 2004-06-30 | 0.32 | 0.34 | 0.02 | 6 | ||
2004-04-30 | 2004-03-31 | 0.34 | 0.4 | 0.06 | 17 | ||
2004-03-02 | 2003-12-31 | 0.32 | 0.24 | -0.08 | 25 | ||
2003-10-14 | 2003-09-30 | 0.25 | 0.26 | 0.01 | 4 | ||
2003-07-17 | 2003-06-30 | 0.26 | 0.24 | -0.02 | 7 | ||
2003-04-15 | 2003-03-31 | 0.24 | 0.24 | 0.0 | 0 | ||
2003-01-30 | 2002-12-31 | 0.26 | 0.26 | 0.0 | 0 | ||
2002-10-16 | 2002-09-30 | 0.21 | 0.22 | 0.01 | 4 | ||
2002-07-17 | 2002-06-30 | 0.19 | 0.2 | 0.01 | 5 | ||
2002-04-18 | 2002-03-31 | 0.16 | 0.17 | 0.01 | 6 | ||
2002-01-29 | 2001-12-31 | 0.16 | 0.16 | 0.0 | 0 | ||
2001-10-18 | 2001-09-30 | 0.16 | 0.16 | 0.0 | 0 | ||
2001-07-19 | 2001-06-30 | 0.15 | 0.15 | 0.0 | 0 | ||
2001-04-19 | 2001-03-31 | 0.12 | 0.12 | 0.0 | 0 | ||
2001-01-29 | 2000-12-31 | 0.11 | 0.12 | 0.01 | 9 | ||
2000-10-16 | 2000-09-30 | 0.1 | 0.1 | 0.0 | 0 | ||
2000-07-18 | 2000-06-30 | 0.08 | 0.09 | 0.01 | 12 | ||
2000-04-20 | 2000-03-31 | 0.02 | 0.02 | 0.0 | 0 | ||
2000-02-02 | 1999-12-31 | 0.07 | 0.05 | -0.02 | 28 | ||
1999-10-18 | 1999-09-30 | 0.07 | 0.07 | 0.0 | 0 | ||
1999-07-22 | 1999-06-30 | 0.13 | 0.13 | 0.0 | 0 | ||
1999-04-20 | 1999-03-31 | 0.03 | 0.04 | 0.01 | 33 | ||
1999-02-09 | 1998-12-31 | 0.04 | 0.05 | 0.01 | 25 | ||
1998-10-20 | 1998-09-30 | -0.01 | 0.02 | 0.03 | 300 | ||
1998-07-20 | 1998-06-30 | 0.06 | 0.09 | 0.03 | 50 | ||
1998-04-20 | 1998-03-31 | 0.01 | 0.03 | 0.02 | 200 | ||
1998-02-05 | 1997-12-31 | 0.05 | 0.06 | 0.01 | 20 | ||
1997-11-11 | 1997-09-30 | -0.06 | -0.08 | -0.02 | 33 | ||
1997-08-04 | 1997-06-30 | -0.07 | -0.04 | 0.03 | 42 | ||
1997-05-08 | 1997-03-31 | -0.05 | -0.02 | 0.03 | 60 | ||
1997-02-21 | 1996-12-31 | -0.02 | 0.01 | 0.03 | 150 | ||
1996-10-30 | 1996-09-30 | -0.05 | -0.04 | 0.01 | 20 | ||
1996-07-25 | 1996-06-30 | -0.04 | -0.04 | 0.0 | 0 | ||
1996-05-02 | 1996-03-31 | -0.06 | 0.02 | 0.08 | 133 | ||
1996-02-14 | 1995-12-31 | -0.03 | 0.02 | 0.05 | 166 | ||
1995-10-24 | 1995-09-30 | -0.05 | -0.05 | 0.0 | 0 |
Biogen Corporate Executives
Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael CPA | Executive CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.02) | Earnings Share 11.06 | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets |
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.